If you could love only one – Forbes
If you could love only one – Forbes
Articles by Asensio.com
Able Telcom’s stock rises after analyst issues false report.
Last week Kaufman Bros., L. P. issued a report claiming that Able Telcom Holding Corp.’s (NASD: ABTE) (Price: $8.50) MFS Network Technologies, Inc.’s (“NT”) subsidiary has fiber assets in The State of New York that […]
State hits E-ZPass company with fines – The Star-Ledger
State hits E-ZPass company with fines – The Star-Ledger
Able Telcom unit charged with defaulting on project – The Miami Herald
Able Telcom unit charged with defaulting on project – The Miami Herald
Able Telcom defaults on stock registration obligation and fails to repay notes.
Able Telcom Holding Corp. (Symbol: ABTE) (Price: $7.75) has failed to have the U.S. Securities and Exchange Commission (“SEC”) declare a registration statement covering its common stock effective. The registration is required by its Convertible […]
Able Telcom declared in default of New Jersey E-ZPass project contract.
Investors may be buying Able Telcom Holding Corp. (Symbol: ABTE) (Price: $7.75) shares believing that its recently acquired MFS Network Technologies, Inc. subsidiary (“MFSNT”) is in compliance with a contract to build an E-ZPass system […]
Casting a long shadow on Wall Street – Financial Post
Casting a long shadow on Wall Street – Financial Post
Amanda Lang Financial Post 1/2/1999
Asensio casts a long shadow on Wall Street […] there is little question that Mr. Asensio is intent on his work. Amanda Lang, Financial Post
Killer Stocks – Forbes
Killer Stocks – Forbes
A perplexing performance – Miami Daily Business Review
A perplexing performance – Miami Daily Business Review
Turbodyne makes futile attempt to gain credibility.
Turbodyne Technologies, Inc. (NASDAQ/EASDAQ Symbol: TRBD) (Price: $4.125) has not served any lawsuit or notice of lawsuit on either Asensio & Company, Inc. or Manuel P. Asensio, its Chairman, President and Chief Executive Officer. Turbodyne […]
Solv-Ex shareholders back company with cash – The National Post
Solv-Ex shareholders back company with cash – The National Post
Leading researchers find CFS to be psychosomatic.
Hemispherx Biopharma Inc.’s (AMEX symbol: HEB) (Price: $6.50) most recent fraudulent stock promotion and insider warrant exercise program is based on its claim that Chronic Fatigue Syndrome (“CFS”) is a “real” disease and that an […]
Solv-Ex launches massive lawsuit – The National Post
Solv-Ex launches massive lawsuit – The National Post
Borsen-Detektiv jagt faule Firmen – EURO am Sonntag
Borsen-Detektiv jagt faule Firmen – EURO am Sonntag
Euro am Sonntag 11/22/98
Manuel Asensio and his team of analysts have made it to their passion to detect fraud in the securities market Katja Dofel, Euro am Sonntag
Hemispherx report reveals insider “pump and dump” operation.
Hemispherx Biopharma, Inc. (AMEX symbol: HEB) (Price: $7.375) reported 24,692,340 outstanding shares as of September 30, 1998 in its Form 10-Q filed with the United States Securities and Exchange Commission on November 11, 1998. This […]
Battle of the Boards – The Standard.com
Battle of the Boards – The Standard.com
Craig Karmin The New Republic 11/9/98
Few doubt that Asensio is battle tested. Craig Karmin, The New Republic
Hemispherx says it’s under attack – Philadelphia Business Journal
Hemispherx says it’s under attack – Philadelphia Business Journal
What do BioTime Investors See That The Rest of World Doesn’t? – San Francisco Chronicle
What do BioTime Investors See That The Rest of World Doesn’t? – San Francisco Chronicle
BioTime officers retract statements regarding FDA approval.
On October 26, 1998 Asensio & Company, Inc. released a report concerning expectations for Hextend’s FDA marketing approval. The report stated that management fostered a belief that approval would be expedited. Also on October 26th, […]
BioTime loses its prime sponsor.
David K. Crossen, an analyst covering BioTime, Inc. (Symbol: BTIM) (Price: $11.75) is no longer employed at NationsBanc Montgomery Securities, Inc. Mr. Crossen wrote at least 19 reports on BioTime. The reports contained numerous material […]
Weird Science: Hedge your biotech portfolio by shorting this stock over $8 – Taipan
Weird Science: Hedge your biotech portfolio by shorting this stock over $8 – Taipan
Hemispherx’s CFS prevalence disclosures proven false.
Hemispherx Biopharma, Inc. (AMEX symbol: HEB) (Price: $7.25) has issued press releases and an investor publication titled “General Information on Chronic Fatigue Syndrome” that report false and exaggerated, national U.S. prevalence rates for Chronic Fatigue […]
Hemispherx confirms failure to disclose FDA violation.
Hemispherx Biopharma, Inc. (AMEX Symbol: HEB) (Price: $7.25) confirmed that it had an “exchange of communications” with the U.S. Food and Drug Administration (“FDA”) a week prior to its 6:00 P.M. EST, Friday, October 23, […]
Hemispherx issues false and exaggerated CFS prevalence rates.
Hemispherx Biopharma, Inc. (AMEX symbol: HEB) (Price: $7.25) has issued press releases and an investor publication titled “General Information on Chronic Fatigue Syndrome” that report false and exaggerated, national U.S. prevalence rates for Chronic Fatigue […]
Lyondell grossly overvalued.
Bloomberg featured an article on September 8, 1998 titled “Welcome to My Short-Selling Contest” that describes John Dorfman’s Short-Selling contest. The goal of the contest is to pick the stock that will decline the most […]
Hemispherx issues blatantly false FDA infraction statement.
Hemispherx Biopharma, Inc. (AMEX symbol: HEB) (Price: $7.625) issued a press release on October 23, 1998 titled “Hemispherx Complying with FDA Request.” This press release failed to disclose that the U.S. Food and Drug Administration […]
FDA determines Hemispherx’s Ampligen claims violate regulations.
The U.S. Food and Drug Administration (“FDA”) notified Hemispherx Biopharma, Inc. (AMEX symbol: HEB) (Price: $7.625) in a Notice of Infraction letter dated October 15, 1998 (“Notice”) that its claims of safety and efficacy for […]